The multiple applications of tamoxifen: An example pointing to SERM modulation being the aspirin of the 21st century

Medical Science Monitor

Volumn 14, Issue 9, 2008, Pages

  Singh, Maneesh N ^a,b   Martin Hirsch, Pierre L ^a,b   Martin, Francis L ^b  

^a LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Estrogen receptor; Neurological disease; SERM; Tamoxifen; Urological cancer

Indexed keywords

ACETYLSALICYLIC ACID; CLOMIFENE CITRATE; ESTROGEN RECEPTOR; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AUTOIMMUNITY; BLADDER CARCINOGENESIS; BREAST CANCER; CANCER PREVENTION; DRUG INDICATION; DRUG MECHANISM; DRUG USE; ENDOMETRIUM CARCINOMA; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; OVARY POLYCYSTIC DISEASE; PARKINSON DISEASE; PROSTATE CARCINOMA; REVIEW; THROMBOEMBOLISM;

ANIMALS; AUTOIMMUNE DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; URINARY BLADDER NEOPLASMS;

EID: 52249083282     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Cuzick J, Powles T, Veronesi U et al: Overview of the main outcomes in breast cancer prevention trials. Lancet, 2003; 36: 296-300
2. Cuzick J, Forbes JF, Sestak I et al: Long-term results of tamoxifen prophylaxis for breast cancer- 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst, 2007; 99: 272-82
3. Powles TJ, Ashley S, Tidy A et al: Twenty year follow-up of the Royal Marsden randomized, double blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst, 2007; 99: 283-90
4. Singh MN, Stringfellow HF, Paraskeveidis E et al: Tamoxifen: Important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev, 2007; 33: 91-100
5. Rosano GM, Vitale C, Fini M: Hormone replacement therapy and Cardioprotect ion: what is good and what is bad for the cardiovascular system? Ann NY Acad Sci, 2006; 1002: 341-48
6. Wang JM, Irwin RW, Brinton RD: Activation of estrogen receptor α increases and estrogen receptor β decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc Natl Acad Sci USA, 2006; 103: 16983-88
7. Koehler KF, Helguero LA, Haldosen L et al: Reflections on the discovery and significance of estrogen receptor β. Endocrin Rev, 2005; 26: 465-78
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 1998; 351: 1451-67
9. Chang J, Powles TJ, Ashley SE et al: The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol, 1996; 7: 671-75
10. Bradbury BD, Lash TL, Kaye JA, Jick SS: Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer, 2005; 103: 1114-21
11. Rutqvirt LE, Mattsson A: Cardiac and thromboembolic morbidity among post-menopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm breast cancer study group. J Natl Cancer Inst, 1993; 85: 1398-406
12. Vaglio A, Salvarani C, Buzio C: Retroperitoneal fibrosis. Lancet, 2006; 367: 241-51
13. Spremulli E, DeSimone P, Durant J: A phase II study Nolvadex: tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma. Am J Clin Oncol, 1982; 5: 149-53
14. Skoog I, Gustafson D: HRT and dementia. J Epidemiol Biostat, 1999; 4: 227-51, discussion 252
15. Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in post-menopausal women: effects on cognitive function and dementia. JAMA, 1998; 279: 688-95
16. LeBlanc ES, Janowsky J, Chan BK, Nelson HD: Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA, 2001; 285: 1489-99
17. Yaffe K, Krueger K, Cummings SR et al: Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the multiple outcomes of raloxifene evaluation (MORE) randomized trial. Am J Psychiatry, 2005; 162: 683-90
18. O'Neill K, Chen S, Brinton RD: Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol, 2004; 185: 63-80
19. Hornykiewicz O: Biochemical aspects of Parkinson's disease. Neurology, 1998; 51: S2-S9
20. Miyawaki E, Lyons K, Pahwa R et al: Motor complications of chronic levodopa therapy in Parkinson's disease. Clinical Neuropharmacology 1997; 20: 523-30
21. Ragonese P, D'Amelio M, Savettieri G: Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann NY Acad Sci, 2006; 1089: 373-82
22. Bondy SC, Lee DK: Oxidative stress induced by glutamate receptor agonists. Brain Res, 1993; 610: 229-33
23. Morale MC, Serra PA, L'Episcopo F et al: Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience, 2006; 138: 869-78
24. Liu X, Fan XL, Zhao Y et al: Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both oestrogen receptor-α and estrogen receptor-β in microglia. J Neurosci Res, 2005; 81: 653-65
25. Chase TN, Oh JD, Konitsious S: Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol, 2000; 247(Suppl.2): II36-42
26. Marin C, Jimenez A, Bonastre M et al: Non-NMDA receptor mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse, 2000; 36: 267-74
27. Oh JD, Geller AJ, Zhang G, Chase TN: Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Res, 2003; 971: 18-30
28. Robertson DW, Katzenellenbogen JA, Long DJ et al: Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem, 1982; 16: 1-13
29. Smith CP, Oh JD, Bibbiani F et al: Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology, 2007; 52: 515-26
30. O'Neill K, Chen S, Diaz Brinton R: Impact of the selective estrogen receptor modulator, tamoxifen, on neural outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Exp Neurol, 2004; 188: 268-78
31. Bascunan-Castillo EC, Enckson RP et al: Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C. J Appl Genet, 2004; 45: 461-67
32. Chaurasia CS, Chen CE, Rubin J, Dewey SL: Effects of tamoxifen on striatal dopamine and 5-hydroxytryptamine release in freely moving male rats: an in-vivo microdialysis investigation. J Pharm Pharmacol, 1998; 51: 1377-85
33. El-Etr M, Vukusic S, Gignoux L et al: Steroid hormones in multiple pregnancy. J Neurol Sci, 2005; 233: 49-54
34. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR: Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol, 2004; 146: 209-15
35. Morales LB, Loo KK, Liu HB et al: Treatment with an estrogen receptor α ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci, 2006; 26: 6823-33
36. Ellos MM, Phiel K, Henderson RA et al: Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J Endocrinol, 2005; 185: 243-52
37. Offner H, Vandenbark AA: Congruent effects of estrogen and T-cell receptor peptide therapy on regulatory T cells in EAE and MS. Int Rev Immunol, 2005; 24: 447-77
38. Wu WM, Lin BF, Su YC et al: Tamoxifen decreases renal inflammation and alleviates disease seventy in autoimmune NZB/W F1 mice. Scand J Immunol, 2000; 52: 393-400
39. Lahita RG: The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol, 1999; 11: 352-56
40. Roubinian JR, Talal N, Greenspan JS et al: Effect of castration and sex hormone treatment on survival, anti-nucleic aad antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med. 1978; 147: 1568-83
41. Peeva E, Venkatesh J, Diamond B: Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol, 2005; 175: 1415-23
42. Shen SS, Smith CL, Hsieh JT et al: Expression of estrogen receptors-α and -β in bladder cancer cell lines and human bladder tumor tissue. Cancer, 2006; 106: 2610-16
43. Ragavan N, Hewitt P, Cooper LJ et al: CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett, 2004; 215: 69-78
44. Lau KM, LaSpina M, Long J, Ho SM: Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res, 2000; 60: 317.5-82
45. Glick JH, Wein A, Padavic K et al: Phase II trial of tamoxifen in metastatic carcinoma of the prostate. Cancer, 1932, 49: 1367-72
46. Singh PB, Matanhelia SS, Martin FL: A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating agent. Eur J Cancer, 2008; 44: 928-36
47. Singh MN, Stringfellow HF, Walsh MJ et al: Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology, 2008; 249: 85-90
48. th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death? J Clin Oncol, 2008; 26: 3073-82
49. Jordan VC: Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer, 2007; 7: 46-53